Prostate Cancer in the Arab World: A View From the Inside

Hilal, Lara; Shahait, Mohammed; Mukherji, Deborah; Charafeddine, Maya; Farhat, Zein; Temraz, Sally; Khauli, Raja B.; Shamseddine, Ali

doi:10.1016/j.clgc.2015.05.010

Cited by 39 publications

(38 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Globally, prostate cancer is reported to be the sixth most common type of cancer, and the second most common in men, especially in Europe, North America, and parts of Africa [24-25]. Studies are underway to evaluate new tests for PCa that could distinguish more aggressive cancers from those less likely to be lethal, to identify men at higher risk of developing prostate cancer, and to enable more efficient use of PSA testing [26].…”

Section: Discussionmentioning

confidence: 99%

Expression of ERG Protein and TMRPSS2-ERG Fusion in Prostatic Carcinoma in Egyptian Patients

Abdelhady

El-Hindawi

Hammam

et al. 2017

Open Access Maced J Med Sci

View full text Add to dashboard Cite

AIM:Prostate cancer (PCa) is the second most common cancers in men worldwide. Its incidence can be influenced by several risk factors including genetic susceptibility. Therefore the search for the expression of a certain gene (ERG) and its rearrangement could give us clues for proper identification of PCa. And the study of ERG expression and its comparison to FISH in Egyptian patients can show whether ERG immunophenotype could be used instead of FISH, as it is cheaper.MATERIALS AND METHODS:This study was performed on 85 cases of PCa, showing 30 cases with HGPIN and 30 cases of prostatic hyperplasia. All were immunohistochemistry stained using ERG monoclonal rabbit antihuman antibody was used (clone: EP111). FISH analysis was performed in 38 biopsies of PCa cases to detect TMRPSS2-ERG rearrangement using the FISH ZytoLight TriCheck Probe (SPEC TMRPSS2-ERG).RESULTS:ERG expression was found in 26% of PCa cases and 20% of HGPIN cases. FISH analysis showed fusion of 21 cases of PCa (out of 22 cases showing ERG immunoexpression).CONCLUSION:Our findings emphasise that only malignant and pre-malignant cells and not benign cells from the prostate stain positive. ERG expression may offer a simpler, accurate and less costly alternative for evaluation of ERG fusion status in PCa.

show abstract

Section: Discussionmentioning

confidence: 99%

Expression of ERG Protein and TMRPSS2-ERG Fusion in Prostatic Carcinoma in Egyptian Patients

Abdelhady

El-Hindawi

Hammam

et al. 2017

Open Access Maced J Med Sci

View full text Add to dashboard Cite

show abstract

“…The use of serum PSA in most countries has also raised increased detection rate and concomitant increased prevalence rate [11,12]. Some literature findings show that the prevalence rate in Asia has decreased to 31.12% [13], while in the Arab world the opposite has been reported [14].…”

Section: Discussionmentioning

confidence: 99%

Pattern and Presentation of Prostate Cancer at a Referral Centre in the Brong Ahafo Region of Ghana; A 10-Year Retrospective Study

2020

JNH

View full text Add to dashboard Cite

Introduction: Prostate cancer is gradually reaching a very high incidence in Africa, especially in the Sub-Saharan region. Understanding the dynamics in occurrence of the disorder is one approach to developing effective public health programmes and interventions that will help curb the rising incidence. Objective: This study was aimed at providing comprehensive and credible data on prostate cancer by assessing the incidence, trend and presentation in the Brong Ahafo Region of Ghana. We sought to provide region-specific hardcore data that will help to assess the issue and provide remedies. Methodology: All prostate disease cases recorded from the year 2009 to 2018 were retrospectively reviewed. Subjects from 40 years and above were eligible for screening. Diagnostic and screening tools for prostate cancer at the study site include family history, serum prostate specific antigen (PSA) test, digital rectal examination, urological ultrasound scan and histopathology (biopsy). Age, PSA values and year of screening/diagnosis were also retrieved from patient folders for the study. Histological findings and parameters considered in the study included diagnosis, carcinoma grading, perineural invasion (PNI) and percentage of affected tissues (%TA). Results: Prostate cancer cases were 369, representing 36.4% of the 1,014 prostate diseases studied. The highest annual incidence was recorded in 2014 with 51 cases (13.8%). The ages of patients ranged from 46 to 101 years with a modal age range of 70 - 79 years and a mean ± SD of 72.2 ± 9.8. The mean PSA value recorded was 37.1ng/ml (±107.3) with predominance in the 11 - 20.9 ng/ml range. Majority of Group Grade 2-5 (79%) constituted progressive prostate cancer. There was no significant correlation (p = 0.091) between grade of prostate cancer and perineural invasion. Conclusion: There is a high incidence of prostate cancer in the Brong Ahafo Region of Ghana (32 per 100,000), predominantly advanced prostatic carcinoma. Reported cases also show high %TA (38.7%) and PNI (38.0%). Early screening for prostate diseases should be encouraged to avoid progression to advanced stage and public health interventions are needed to address some of these issues.

show abstract

“…However, demographic issues, referral patterns, and the prevalence of specific diseases in the KSA may also be implicated. RARP, the procedure most widely performed globally, where the magnitude of prostate cancer is very high, is significantly different from the Middle East [42]. It should be mentioned that all these robotic systems were installed in governmental hospitals, limiting the advertising and awareness of these services.…”

Section: Urological Ras In the Middle Eastmentioning

confidence: 99%

Robot-assisted urological surgery in the Middle East: Where are we and how far can we go?

Azhar

Elkoushy

Aldousari

2019

Arab Journal of Urology

View full text Add to dashboard Cite

Objectives: To evaluate robot-assisted surgery (RAS) in Urology in the Middle East, and its status and future perspectives. Methods: A Medical Literature Analysis and Retrieval System Online (MEDLINE) search was performed using the following keywords: 'robotics', 'robot-assisted surgery', 'laparoscopy', at first with each specific procedure name, such as radical cystectomy, followed by 'Middle East' and country names. All abstracts and articles in English that adhered to the scope of the current issue were selected, giving special consideration to relevant landmark articles and those describing trends and the future of RAS in Urology. Results: Only a few index case reports characterised RAS in the Middle East. The Middle East possess only 1% of the da Vinci® Surgical Systems (Intuitive Surgical Inc., Sunnyvale, CA, USA) installed worldwide, including 19 in Saudi Arabia; six in Qatar; two in each of Kuwait and Lebanon; three in the United Arab Emirates; and only one in Egypt. The total number of RAS performed in the Middle East is low compared to Europe and the USA. Many countries in the Middle East still lack surgical robots despite having the expertise and appropriate caseload, whilst others seem not to utilise the surgical robot at a suitable rate, as reflected by the sparse number of operated cases and outgoing publications. There are major differences in RAS availability, usage, and perception according to the geographical place of practice and acceptance of robots by surgeons and patients. Conclusion: RAS in Urology continues to grow in the Middle East, with increasing caseloads and diversity of operated cases. Acceptance of robots by Middle East surgeons is significantly increasing.

show abstract

Prostate Cancer in the Arab World: A View From the Inside

Cited by 39 publications

References 39 publications

Expression of ERG Protein and TMRPSS2-ERG Fusion in Prostatic Carcinoma in Egyptian Patients

Expression of ERG Protein and TMRPSS2-ERG Fusion in Prostatic Carcinoma in Egyptian Patients

Pattern and Presentation of Prostate Cancer at a Referral Centre in the Brong Ahafo Region of Ghana; A 10-Year Retrospective Study

Robot-assisted urological surgery in the Middle East: Where are we and how far can we go?

Contact Info

Product

Resources

About